THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Vibhuti Agrahari to Humans

This is a "connection" page, showing publications Vibhuti Agrahari has written about Humans.
Connection Strength

0.420
  1. Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges. Biomaterials. 2020 11; 260:120163.
    View in: PubMed
    Score: 0.040
  2. Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv Drug Deliv Rev. 2019 08; 148:146-180.
    View in: PubMed
    Score: 0.037
  3. Special Issue on Advanced Drug Delivery Approaches for Inner Ear Therapeutics. Eur J Pharm Sci. 2019 Jan 01; 126:1-2.
    View in: PubMed
    Score: 0.036
  4. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discov Today. 2018 05; 23(5):974-991.
    View in: PubMed
    Score: 0.034
  5. Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells. Nanomedicine (Lond). 2017 Aug; 12(16):1911-1926.
    View in: PubMed
    Score: 0.033
  6. Inner ear targeted drug delivery: what does the future hold? Ther Deliv. 2017 04; 8(4):179-184.
    View in: PubMed
    Score: 0.032
  7. Recent Patents and Emerging Therapeutics on Ocular Inflammation and Allergy. Recent Pat Inflamm Allergy Drug Discov. 2017; 11(2):92-106.
    View in: PubMed
    Score: 0.032
  8. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2017 10; 14(10):1145-1162.
    View in: PubMed
    Score: 0.032
  9. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016 12; 6(6):735-754.
    View in: PubMed
    Score: 0.032
  10. Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules. Mol Pharm. 2016 09 06; 13(9):2912-22.
    View in: PubMed
    Score: 0.030
  11. Polyphenols against infectious diseases: Controlled release nano-formulations. Eur J Pharm Biopharm. 2021 Apr; 161:66-79.
    View in: PubMed
    Score: 0.011
  12. Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation. Int J Nanomedicine. 2019; 14:8847-8859.
    View in: PubMed
    Score: 0.010
  13. Extracellular Microvesicles as New Industrial Therapeutic Frontiers. Trends Biotechnol. 2019 07; 37(7):707-729.
    View in: PubMed
    Score: 0.009
  14. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Adv Drug Deliv Rev. 2018 02 15; 126:67-95.
    View in: PubMed
    Score: 0.009
  15. Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery. Mol Pharm. 2017 06 05; 14(6):2056-2069.
    View in: PubMed
    Score: 0.008
  16. Transporter effects on cell permeability in drug delivery. Expert Opin Drug Deliv. 2017 Mar; 14(3):385-401.
    View in: PubMed
    Score: 0.008
  17. Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul. 2016; 33(2):103-13.
    View in: PubMed
    Score: 0.008
  18. Novel delivery approaches for cancer therapeutics. J Control Release. 2015 Dec 10; 219:248-268.
    View in: PubMed
    Score: 0.007
  19. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. AAPS PharmSciTech. 2016 Apr; 17(2):294-306.
    View in: PubMed
    Score: 0.007
  20. Monocarboxylate transporter mediated uptake of moxifloxacin on human retinal pigmented epithelium cells. J Pharm Pharmacol. 2014 Apr; 66(4):574-83.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES